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ABSTRACT
In chronic hepatitis B (CHB), failure to control hepatitis B virus (HBV) is associated with T cell dysfunction. HBV transgenic
mice mirror many features of the human disease, including T cell unresponsiveness, and thus represent an appropriate model in
which to test novel therapeutic strategies. To date, the tolerant state of CD8 T cells in these animals could be altered only by
strong immunogens or by immunization with HBV antigen-pulsed dendritic cells; however, the effectors induced were unable to
suppress viral gene expression or replication. Because of the known stimulatory properties of alpha interferon (IFN-) and in-
terleukin-15 (IL-15), this study explored the therapeutic potential of liver-directed gene transfer of these cytokines in a murine
model of CHB using adeno-associated virus (AAV) delivery. This combination not only resulted in a reduction in the viral load
in the liver and the induction of an antibody response but also gave rise to functional and specific CD8 immunity. Further-
more, when splenic and intrahepatic lymphocytes from IFN-- and IL-15-treated animals were transferred to newHBV carriers,
partial antiviral immunity was achieved. In contrast to previous observations made using either cytokine alone, markedly atten-
uated PD-L1 induction in hepatic tissue was observed upon coadministration. An initial study with CHB patient samples also
gave promising results. Hence, we demonstrated synergy between two stimulating cytokines, IL-15 and IFN-, which, given to-
gether, constitute a potent approach to significantly enhance the CD8 T cell response in a state of immune hyporesponsiveness.
Such an approachmay be useful for treating chronic viral infections and neoplastic conditions.
IMPORTANCE
With 350 million people affected worldwide and 600,000 annual deaths due to HBV-induced liver cirrhosis and/or hepatocellu-
lar carcinoma, chronic hepatitis B (CHB) is a major health problem. However, current treatment options are costly and not very
effective and/or need to be administered for life. The unprecedented efficacy of the strategy described in our paper may offer an
alternative and is relevant for a broad spectrum of readers because of its clear translational importance to other chronic viral
infections in which a hyporesponsive antigen-specific T cell repertoire prevents clearance of the pathogen.
Worldwide, 350 million people suffer from chronic hepatitis B(CHB), and approximately 600,000 people die annually be-
cause of hepatitis B virus (HBV)-induced liver cirrhosis and/or hep-
atocellular carcinoma (1). The host immune response to HBV anti-
gens is a critical factor determining the outcome of infection. While
patients with self-limited, acuteHBVdevelop strong,multispecific T
cell responses toviral antigens, these responsesareweakandnarrowly
focused in chronic HBV carriers (2, 3). In these patients, HBV-spe-
cific CD4 and CD8 T cells display an exhausted phenotype char-
acterized by failure to proliferate and failure to produce gamma in-
terferon (IFN-), tumor necrosis factor alpha (TNF-), and
interleukin-2 (IL-2) after stimulation with viral antigens (4, 5).
A cytokine that has received much attention for the treatment
of chronic hepatitis B andC infections is IFN-. As a recombinant
protein, it has been demonstrated to be effective in a proportion of
patients (6, 7); however, patients with high viral loads and normal
serum transaminase levels seem particularly resistant to IFN-
therapy (8). While IFN- was shown to have a direct degrading
effect on viralDNA (9) and to induce the expansion and activation
of NK cells (10), it did not effectively support the expansion
and/or survival of CD8 T cells from patients with CHB (8). In-
terestingly, IFN- can facilitate the response of CD8 T cells to
IL-15 stimulation by inducing the expression of IL-15 receptor
subunit alpha (IL-15R) (11). Moreover, there is evidence indi-
cating that long-lasting persistence of IFN--primedCD8T cells
is favored by their enhanced responsiveness to IL-15 (12).
IL-15 is a powerful stimulatory cytokine that plays a key role in
lymphocyte function and homeostasis. It is involved in various
activation, proliferation, and differentiation processes of CD8 T
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cells (13), NK cells (14), and CD4 T cells (15, 16). IL-15 has been
reported to be capable of rescuing tolerant CD8 T cells for use in
adoptive immunotherapy of established tumors (17), and in com-
bination with retinoic acid, it abrogated tolerance to dietary anti-
gens (18). Importantly, hepatic overexpression of IL-15 has re-
cently been implicated in inducing an anti-HBV response,
possibly by mediating IFN- induction (19).
This study explored the therapeutic potential of liver-directed
gene transfer of IFN- and IL-15, alone or in combination, in a
murine model of chronic HBV (20) by use of adeno-associated
virus (AAV) delivery. Despite their limitations, HBV transgenic
(HBVTg) mice are widely used for elucidating immune responses
in CHB and evaluating therapeutic strategies for CHB (21). To
date, it has been shown that strong immunogens or immunization
with HBV antigen-pulsed dendritic cells was able to alter the tol-
erant state of CD8T cells in these animals; however, the effectors
induced were unable to suppress viral gene expression or replica-
tion (22, 23). The results presented here show that combining
IL-15 with IFN- resulted in a functional and specific CD8 re-
sponse, which was reflected by a decrease in the level of HBV core
antigen (HBcAg) in the liver, and could confer partial immunity
upon splenocyte transfer to HBV-infected recipients.
MATERIALS AND METHODS
Animals andmanipulations.HBVTgmicewere kindly provided by Fran-
cis V. Chisari (20). Mice were bred and maintained under pathogen-free
conditions at the animal facility of the University of Navarra. For experi-
ments, they werematched for age (6 to 10 weeks), sex (male), and levels of
HBV DNA and HBV surface antigen (HBsAg) in serum. Age-matched
C57BL/6 wild-type (WT) males were purchased from Harlan Laborato-
ries (Barcelona, Spain). The experimental design was approved by the
Ethical Committee for Animal Testing of the University of Navarra.
For all procedures, animals were anesthetized by intraperitoneal injec-
tion of a mixture of xylazine (Rompun 2%; Bayer) and ketamine (Imal-
gene 500; Merial) (1:9, vol/vol).
HBVTg mice were injected intravenously (i.v.) with AAV at a dose of
1.5  1012 viral genomes (vg)/kg, except for the control group, which
received 3 1012 vg/kg.
Blood was collected by bleeding from the retro-orbital plexus, and
serum samples were obtained by centrifugation of total blood.
For adoptive transfer experiments, C57BL/6mice were injected with a
recombinant AAV vector (5 1012 vg/kg) carrying the HBV 1.3 genome
as described previously (28) in order to establish an alternative model of
chronic HBV infection. Donor cells, consisting of 106 intrahepatic lym-
phocytes (IHL) and 107 splenocytes, were injected i.v. into the retro-or-
bital plexus in a final volume of 125 l.
Viral construction, production, and purification. The recombinant
AAV8 (rAAV8) vector with WT AAV2 inverted terminal repeats (ITRs)
was produced as described previously (24, 25). The expression cassette in
the AAV–IL-15 vector consists of themurine IL-15 gene (GenBank acces-
sion number DQ083237.1) under the regulation of a liver-specific pro-
moter (25). The expression cassette in the AAV–IFN- vector has been
described previously and contains of the murine IFN-1 gene under the
regulation of the elongation factor 1 promoter (24). A luciferase-encod-
ing AAV (AAV-LUC) served as a control (24).
DNA and RNA analysis. Total DNA and RNA were isolated from
livers as described previously (25). Real-time PCR-based quantification of
HBcAg and glyceraldehyde-3-phosphate dehydrogenase (GADPH) DNA
and RNA was performed using SYBR green master mix (Applied Biosys-
tems, Foster City, CA). The following primers were used: HBcAg sense
(5=-TTCGCACTCCTCCAGCTTAT-3=) and antisense (5=-GGCGAGGG
AGTTCTTCTTCTA-3=), GAPDH sense (5=-TGCACCACCAACTGCTT
A-3=) and antisense (5=-CAGAAGACTGTGGATGGCCCCTC-3=), and
luciferase sense (5=-TCGAGGAGCCTTCAGGATT-3=) and antisense (5=-
TTTTGGCGAAGAAGGAGAAT-3=).
HBV DNA was isolated from 20-l serum samples using the High
Pure viral nucleic acid kit (Roche).
For Southern blot analysis of HBV replication intermediates, frozen liver
and kidney tissues weremechanically pulverized, and total DNAwas isolated
and was digested with HindIII as described previously (20). Before electro-
phoresis, all DNA samples were digested with RNase A (Roche) at 10mg/ml
and 37°C overnight (o/n). Nylon filters (Hybond-N; Amersham) were hy-
bridized with a 32P-radiolabeled HBV-specific DNA probe.
Determination of serumALT levels. Levels of alanine aminotransfer-
ase (ALT) in blood were measured using commercial kits (Sigma Chem-
icals, St. Louis,MO) and aHitachi automatic analyzer (BoehringerMann-
heim, Indianapolis, IN).
ELISAs for IL-15, IFN-, andHBsAg levels inserum.Theconcentration
of IL-15 in serum was determined using the Mouse IL-15/IL-15R Complex
ELISA (enzyme-linked immunosorbent assay) Ready-SET-Go! set (eBiosci-
ence), and the serum IFN- concentration was determined using the Ver-
iKine Mouse Interferon Alpha ELISA kit (PBL Assay Science). HBsAg levels
were also determined by ELISA (Bioelisa HBsAg 3.0; Biokit).
Liver histology, IHC, and TUNEL staining. Liver sections were fixed
in 4% paraformaldehyde (Panreac), embedded in paraffin, sectioned
(thickness, 5 m), and stained with hematoxylin and eosin (H&E). Im-
munohistochemistry (IHC) for HBcAg (B0586; Dako, Glostrup, Den-
mark) and PD-L1 (ab58810; Abcam) was performed using the EnVision
system (Dako) according to themanufacturer’s recommendations. In situ
detection of cells with DNA double-strand breaks was performed by the
terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end la-
beling (TUNEL) stainingmethodby use of an In SituCellDeathDetection
kit (Roche) according to instructions. Images were acquired digitally with
an Axio Imager. MI microscope (Zeiss, Germany) using an in-house
MetaMorph macro (Molecular Devices, USA). All images were stored in
uncompressed 24-bit color TIFF format. Images were automatically ana-
lyzed using a plugin developed for Fiji, ImageJ, at NIH.
Isolation of IHL.Mice were perfused via the portal vein with 10 ml of
Ca2- andMg2-free phosphate buffer solution preheated to 37°C. After
perfusion, the vena cava was cut and the liver extracted. After incubation
in 10 ml of phosphate-buffered saline (PBS) containing 1,000 U of type II
collagenase (Gibco) for 20min, the liver homogenate was passed through
a 70-m nylon cell strainer, and the cell suspension was centrifuged at
1,200 rpm for 10 min. The cell pellet was resuspended in 40% Percoll and
was centrifuged at 1,800 rpm for 10 min. Red blood cells were removed
using a lysis buffer (Gibco); the remaining cells were washed and were
resuspended in RPMI 1640 medium.
In vitro analysis of lymphocyte proliferation. Intrahepatic lympho-
cytes obtained from HBV transgenic mice treated with LUC, IFN-, IL-
15, or IL-15 plus IFN- were isolated, labeled with carboxyfluorescein
succinimidyl ester (CFSE), and cultured for 3 days in the presence or
absence of 10 g/ml of HBcAg peptide (epitope C93-100). The prolifera-
tion of CD8 T cells was analyzed by flow cytometry.
Antibody and pentamer staining. Cells were labeled with the fol-
lowing antibodies according to the manufacturer’s recommendations:
allophycocyanin (APC)-conjugated CD19 (CD19-APC) (clone PeCa1;
ImmunoTools), CD4-APC/Cy7 (clone GK1.5), CD44-APC/Cy7 (clone
IM7), CD8a-Pacific Blue (clone 53.6.7),NK1.1-APC (clone PK136), PD-1
conjugated with fluorescein isothiocyanate (FITC) or brilliant violet 421
(clone 29F.1A12) (all from BioLegend), and CD8a-FITC (clone 1D3;
eBioscience).
For pentamer staining. 2  106 isolated cells were incubated for 10
min at room temperature (RT) with major histocompatibility complex
(MHC) class I peptide pentamers (H-2Kb/ILSPFLPLL for HBsAg
[epitope S208–216], H-2Kb/MGLKFRQL for HBcAg [epitope C93–100], or
H-2Kb/SIINFEKL for ovalbumin [OVA] [epitope OVA257–264]; Pro-
Immune). Cells were then washed and were stained with the respective
surface antibodies according to the manufacturer’s recommendations.
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Data were acquired with an 8-color BD FACSCanto II system
equipped with three lasers (488 nm, 633 nm, and 405 nm) or with a
4-color FACSCalibur system equipped with two lasers (argon [488 nm]
and diode [635 nm]). Fluorescence-activated cell sorter (FACS) data were
analyzed with FlowJo or DIVA software.
In vivo killing assay (IVK). Splenocytes isolated from HBVTg or WT
mice were pulsed with HBV peptide C93–100 or S208–216, or with an irrel-
evant peptide (ovalbumin; epitope OVA257–264) (all from Think Pep-
tides), for 30 min at 37°C. Cells were then labeled with 5 M (for HBV
peptides) or 0.5M(for the control peptide) CFSE (Invitrogen), and 5
106 cells of each population were transferred intravenously to mice.
Twenty-four hours later, animals were sacrificed, liver and spleen lym-
phocytes isolated, and CFSE staining analyzed by FACS.
Depletionof lymphocyte subpopulations andPD-L1blockade.CD8
T cell depletion studies were performed by intraperitoneal adminis-
tration of 100 g of an anti-mouse CD8 antibody (clone H35-17.2).
Doses were scheduled starting 3 days before vector injection and at
days 0, 3, 7, and 14 after virus injection. Depletion levels were deter-
mined to be 98%. Irrelevant mouse immunoglobulin isotypes were
used as controls. NK cell depletion studies were performed by intra-
peritoneal administration of 200 g of anti-mouse NK1.1 antibodies
(clone PK136). Doses were scheduled daily starting 2 days before virus
injection and at days 1, 3, 7, and 14 after virus injection. Depletion
levels were determined to be98%. Irrelevant mouse immunoglobu-
lin isotypes were used as controls.
For in vivo PD1–PD-L1 blockade, rat anti–mouse PDL-1 (clone
10F.9G2; catalog no. BE0101; BioXCell) or a rat IgG2b isotype-matched
control antibody (LTF-2; catalog no. BE0090; BioXCell) was injected in-
traperitoneally 1 day before AAV–IL-15 or AAV-LUC injection and at
days 0, 3, 6, and 9 after injection.
Patientsandisolationofperipheralbloodmononuclearcells (PBMCs).
PBMCs were isolated by Ficoll gradient centrifugation from heparinized
blood samples taken from a total of 21 patients with CHB. Ethical approval
wasobtained throughUKNHSREC11/LO/0421, andeachpatient gavewrit-
ten informed consent. All patients were negative for anti-HCV and anti-HIV
antibodies and were treatment naïve. Patients had a median age of 40 years
(range, 27 to 60 years), and 2/21 were positive for HBV envelope antigen
(HBeAg). ThemedianHBVDNA levelwas 1,400 international units (IU)/ml
(range, below the limit of quantification [BLQ] to 2 108 IU/ml), and the
median ALT level was 31 IU/liter (range, 18 to 474 IU/liter).
HBV peptide stimulation of human PBMCs. Patient PBMCs were
stimulated with 1 M overlapping long peptides spanning the whole
HBV core protein (genotype D [ayw]; JPT Peptide Technologies) in
the presence or absence of IFN- (103 IU/ml), IL-15 (10 ng/ml; R&D),
or both. Cells were cultured in complete RPMI medium supplemented
with 20 IU/ml IL-2 for 10 days at 37°C. IL-2 and medium were re-
freshed on day 4 of culture. On day 9, PBMCs were restimulated with
1 MHBV peptide in the presence of brefeldin A (1 g/ml; Sigma) for
16 h. For intracellular cytokine staining, cells were fixed and perme-
abilized using a Cytofix/Cytoperm kit (BD Biosciences) for 15 min at
4°C and were then stained with phycoerythrin (PE)-conjugated anti-
granzyme B (anti-GrB; Biolegend) and anti-IFN- BV421 (BD) for 30
min at 4°C. Samples were analyzed using a FACS LSRII flow cytometer
(BD Biosciences).
Statistical analysis.Data are presented as means	 standard errors of
the means (SEM) and were analyzed for significance by the Student t test.
Differences among groups were analyzed by one-way analysis of variance
(ANOVA) followed by a Bonferroni multiple-comparison test using
GraphPad Prism software, version 5.0. (Significance is indicated by aster-
isks in the figures as follows: *, P
 0.05; **, P




For analysis of the reduction of viral replication and the decrease in
the number of HBV core-positive nuclei induced by AAV–IFN- com-
bined with AAV–IL-15, the fold inhibition (FI) for each treatment was
calculated as the ratio of the level of viral RNA obtained from the livers
ofmice treatedwithAAV-LUC to the level of viral RNAobtained from the
livers of mice treated with AAV–IFN- (FIIFN-), AAV-IL-15 (FIIL-15), or
both (FIcombination). The synergy index (S) for the combination of
AAV–IFN- and AAV–IL-15 was calculated as described previously
(47) from the fold inhibition by use of the equation S FIcombination
(FIIFN-  FIIL-15)/(FIIFN-  FIIL-15). The critical value of S is zero
and indicates an additive effect, while a positive value for S shows
synergism.
RESULTS
Antiviral effect of IL-15–IFN- combination treatment in
HBVTg mice. The immunomodulatory potential of IL-15 and
IFN- in a chronic HBV setting was investigated using anHBVTg
mouse model (20). HBVTg mice and C57BL/6 WTmice received
FIG 1 Cytokine expression and reduced HBV nucleic acids. (A and B) Concentrations of the IL-15–IL-15R complex (A) and IFN- (B) in serum after vector
injection. Results are representative of 3 independent experiments and representmeans	 SEM for triplicates. (C andD) Ten days after vector injection, animals
were sacrificed and livers assessed for the presence of HBV DNA (C) and HBV RNA (D). Data were normalized to GADPH levels, and the means	 SEM for 5
to 6 animals/group are shown. *, P
 0.05; **, P
 0.01; ***, P
 0.001.
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a single intravenous (i.v.) injection of AAV–IFN-, AAV–IL-15, a
combination of both, or an equivalent dose of a control vector
expressing the luciferase reporter gene (LUC). Serum cytokine
levels weremeasured at different time points after vector injection
(Fig. 1A and B).
To evaluate the direct antiviral effect elicited by the different
treatments, total HBV-specific DNA and RNA in the liver were
analyzed by quantitative real-time PCR. IFN-, IL-15, and the
combination treatment exerted similar inhibitory effects on HBV
replication (Fig. 1C). However, transcriptional inhibition was
more pronounced in animals that had received the combination
therapy (Fig. 1D) with a significant synergy index (S  3,476 	
FIG2 Synergistic antiviral effect of combined IL-15 and IFN- treatment. (A)HBcAg protein expression in the liver, determined by IHC.A representative image
is shown for each treatment group. (B and C) Fields were analyzed automatically to determine the number of hepatocytes positive for HBcAg in the nucleus (B)
or the area ofHBcAg staining in the cytoplasm (C). Each symbol represents themean value for 10 different sections permouse.Means	 SEM for each group (n
16) are also shown. (D) HBV genome copy numbers 10 days after vector injection. Graphs show means (n 5)	 SEM. *, P
 0.05; ***, P
 0.001; ****, P

0.0001; ns, nonsignificant. (E) HBV replicative intermediates in the liver by Southern blot analysis 10 days after vector injection. RC, relaxed-circular DNA; DS,
double-strandedDNA; SS, single-strandedDNA; Luc, HBVTgmice treated with AAV-Luc; AAV-HBV, C57BL/6WTmice receiving AAV-HBV; IFN-, HBVTg
mouse treated with AAV-IFN-; IL-15, HBVTgmouse treated with AAV-IL15; IFN- IL-15, HBVTgmouse treated with AAV-IFN- AAV-IL-15. Results
from representative animals from each treatment group are shown.
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2,390). The robustness of the antiviral effect of the combined ther-
apy was confirmed by immunohistochemical analysis of HBcAg
expression (Fig. 2A), as well as by a quantitative method, deter-
mining the number of core-positive nuclei per field (Fig. 2B) and
the area of HBcAg cytoplasmic staining per field (Fig. 2C). IFN-
or IL-15 alone reduced the presence of core protein in the cyto-
plasm of hepatocytes but had little effect on the expression of core
protein in the nuclei. In contrast, when combined, IFN- and
IL-15 were able to eliminate nuclear core protein expression,
showing strong synergy (S 4,673	 1,853).
The direct antiviral effects of the different treatments were also
analyzed by measuring the viral load in serum and hepatic HBV
DNA replicative intermediates by Southern blotting. In all treat-
ment groups, viral loads in the serum were significantly reduced
and HBVDNA replicate intermediates in the liver were undetect-
able (Fig. 2D and E).
As an important aspect of the immune response against HBV,
the presence of antibodies against HBsAg was measured by ELISA
20 days after treatment. Animals that had received IFN- alone or
the combination of IFN- and IL-15 developed anti-HBsAg, and
antibody levels were higher in the group receiving the combina-
tion treatment (data not shown).
The IL-15–IFN- combination treatment induces immune-
mediated liver damage in HBVTg mice. Liver histology showed
no signs of inflammation at day 10 posttreatment in HBVTgmice
treated with IFN- or the control, while marked portal and peri-
portal infiltrates were observed in the IL-15 and IL-15–IFN-
groups (data not shown), and this pattern remained unchanged
on day 20 (data not shown). However, on day 20, the livers of the
combination group presented with extensive areas of hepatocel-
lular necrosis surrounded by dense lymphocytic infiltrates (Fig.
3A). TUNEL staining showed large areas of positive nuclei in
HBVTg mice treated with IL-15 plus IFN-, while staining was
negative for all other groups (Fig. 3B and data not shown). In
parallel, marked hypertransaminasemia was observed in these an-
imals (Fig. 3C). Importantly, neither periportal infiltrates nor
liver damage was observed inWTmice subjected to the combina-
tion therapy (Fig. 3A and B; also data not shown).
AAV–IL-15 enhances HBV-specific T cell responses in
HBVTg mice. To explore the nature of the liver infiltrate further,
its cellular composition was analyzed in more detail. IL-15 alone
or in combination with IFN- induced an increase in total lym-
phocyte numbers (data not shown). While IL-15 induced a
marked rise in the number of CD8 T cells and a moderate eleva-
tion of CD4T cells (Fig. 4A), only the number of CD8 cells, not
that of CD4 T cells, was also significantly increased in the com-
bination treatment group. Another cell type that has been impli-
cated in virus control and clearance (reviewed in reference 27), the
NK cell, was found in greatly elevated numbers in response to
IFN-; however, IL-15 seemed to partially counteract this expan-
sion in the combination therapy (Fig. 4A).
Since CD8 T cells are one of the key players in clearing acute
HBV infection, the number of HBV-specific CD8 T cells in the
liver was determined using H-2Kb pentamers specific for HBcAg
epitope C93–100. Both IL-15- and IFN-–IL-15-treated mice
showed significantly more intrahepatic CD8 CD44 pentamer-
positive T cells than the IFN- and control groups (Fig. 4B
and data not shown). Similar results were obtained by using
pentamers specific for HBsAg (data not shown); however, no
OVA-specific T cells were detected in the different treatment
FIG 3 The IL-15–IFN- combination treatment induces immune-mediated liver damage in HBVTg mice but not in WT mice. (A) Representative images of
necroinflammatory lesions in HBVTg (top) and C57BL/6 (bottom) mice on day 20 after vector administration. (B) TUNEL-positive nuclei (right) and
4=,6-diamidino-2-phenylindole (DAPI) staining (left) of the same mice. (C) Serum ALT levels in HBVTg mice at days 10 and 20 after vector administration.
Results are expressed as means	 SEM for 5 to 6 animals/group (***, P
 0.001).
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groups (data not shown). To further characterize the response,
the numbers of HBV-specific CD8 lymphocytes in the liver were
analyzed at different time points after treatment. While in IFN--
treated mice HBcAg-specific CD8 T cells were detected in very
low numbers at day 3 after treatment and increased only moder-
ately thereafter, the number of pentamer-positive cells in the livers
of animals treated with IL-15 or the combination increased signif-
icantly over time. The increase was highest in the IL-15 treatment
group (Fig. 4C). Only a very low pentamer-positive population
could be detected in control animals, and this population is likely
to represent the tolerant HBcAg-specific population. The re-
sponse to HBsAg reflected the response to HBcAg in all groups
(data not shown). Furthermore, while CD8 lymphocyte expan-
sion was observed in the livers of C57BL/6mice treated with IL-15
or IL-15–IFN-, no HBV- or OVA-specific CD8 T cells were de-
tected (data not shown). When isolated intrahepatic lymphocytes
(IHL) were stimulated ex vivo on day 10, a robust proliferative
response to C93–100 (MGLKFRQL) could be observed in IL-15-
and IL-15–IFN--treated animals, and this response was more
intense with the combination treatment (Fig. 4D).
To test if HBV-specific CD8 T cells were able to exert effector
functions, an in vivo killing assay (IVK) was performed 10 days
after the administration of the different treatments. Splenocytes
isolated from HBVTg or WT mice were loaded with epitope
C93–100 or with an irrelevant peptide (OVA257–264), labeled with 5
M or 0.5 M CFSE, respectively, and transferred i.v. to the
groups of mice treated as before. Killing was analyzed 24 h after
transfer. No specific lysis was detected in animals treated with the
control or IL-15 alone, while in mice that had received IFN- or
IFN- plus IL-15, specific killing of HBV peptide-loaded cells
could be observed (Fig. 4E). The percentage of lysis was signifi-
cantly higher with the combination treatment than with IFN-
alone. Similar results were obtained in an IVK assay using HBsAg
epitope S208–215 (ILSPFLPL) (data not shown). No HBV-specific
CD8 T cells or cytotoxic activity was seen in WT mice (data not
shown).
FIG 4 IL-15-induced expansion of HBcAg-specific CD8 T cells requires combination with IFN- to render them functional CTLs. The mononuclear liver
infiltrate was isolated and analyzed on day 10 after vector administration. (A and B) The absolute numbers of CD8, CD4, and NK cells per liver (A) and the
number of HBcAg-specific CD8 T cells per liver (B) are shown (n 7). (C) The increase in the number of HBcAg-specific CD8 T cells was analyzed over time
(n 3/time point). (D) Proliferative response of HBcAg-specific CD8 T cells upon peptide stimulation. In vitro stimulation was performed in triplicate with
cells obtained from 3mice per group. (E) Proportion of lysedHBcAg-loaded target cells in vivo (n 5). Results are representative of 3 independent experiments.
All graphs show means	 SEM. *, P
 0.05; **, P
 0.01; ***, P
 0.001; ****, P
 0.001; ns, nonsignificant.
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CD8Tcellsplayanessential role in theantiviral response to
HBV. To investigate the importance of CD8 T cells and NK cells
in mediating the antiviral response elicited by the combination
therapy, HBVTgmice treated with IL-15 plus IFN-were divided
into three groups. Group 1 was depleted of CD8 T cells; group 2
was depleted of NK cells; and group 3 received an isotype control
antibody. The expression ofHBcAg in the liver, which appeared to
be a sensitive indicator of the intensity of the antiviral response,
was assessed by IHC. As shown in Fig. 5A, depletion of CD8
lymphocytes completely abrogated the antiviral effect of the com-
bination therapy, while NK cell depletion had little impact on the
antiviral response. Moreover, while the combined treatment re-
sulted in an elevation of serum transaminases, this alteration was
absent in the treated transgenic mice subjected to depletion of
CD8 T cells (Fig. 5B). These findings indicate that CD8 lym-
phocytes are the key players in the antiviral response and that the
disappearance of virus from the liver is not solely caused by a
direct antiviral effect of the cytokines.
Importantly, transfer of splenic and intrahepatic lymphocytes
fromHBVTgmice treatedwith IL-15plus IFN-, but not from those
receiving the LUC control, to C57BL/6 mice injected with an AAV
vector carrying the HBV 1.3 genome—another model of chronic
HBV hepatitis (28)—induced moderate hypertransaminasemia as
well as a reduction in HBV viremia (Fig. 5C to E). Additionally, sig-
nificantly lower levels of hepatic HBVRNA could be observed at day
4after transfer (Fig. 5F),whileDNAlevels remainedunchanged(data
FIG 5 Combined IL-15–IFN- treatment confers partial protective CD8 immunity. (A) HBVTg mice treated with AAV–IL-15 plus AAV–IFN- were depleted
of CD8 or NK cells. Hepatic HBcAg expression was analyzed 10 days later. Representative images from each group are shown. (B) Serum ALT levels (IU/liter)
in HBVTg mice depleted of CD8 or NK cells at day 10 after vector administration. (C) Scheme of the adoptive transfer protocol. (D) Serum ALT levels at day
0 and day 4 (d4) post-IHL transfer. (E and F) HBV genome copy numbers (E) and HBV RNA copies (F) on day 4 after IHL transfer. Results are normalized to
GADPH levels. All data are presented as mean (n, 3 to 4)	 SEM. *, P
 0.05; **, P
 0.01; ***, P
 0.001.
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not shown). In contrast, LUC DNA and RNA expression did not
change in controlmice infectedwith AAV-LUCprior to lymphocyte
transfer (data not shown). Taken together, these data suggest that the
antiviral effector functions of lymphocytes rescued from tolerance by
IL-15–IFN- treatment are not a bystander effect and can be trans-
ferred to chronically HBV infectedmice.
IL-15 upregulates PD-1 and PD-L1 in the inflammatory infil-
trate of the liver, an effect counteractedby IFN-.PD-1 andPD-L1
constitute a key control point of the CD8 T cell response and have
been thought to negatively regulate viral responses (5). Since both
PD-1 and PD-L1, the receptor and its ligand, can be upregulated by
IFN- and IL-15 (26, 29–31), their expressionwas analyzed onhepa-
tocytes and IHL. The proportion of intrahepatic PD-1 CD8 cells
was increased in all treatment groups, especially in the presence of
IL-15 (Fig. 6A). Surprisingly coinfectionwith IFN- seemed to offset
this effect to a significant degree.OnNKcells, PD-1upregulationwas
observed only in the context of IL-15, and again, coadministration of
IFN- seemed to dampen this effect (Fig. 6B). When PD-L1 expres-
sion on the surfaces of hepatocytes (Fig. 6C) and relative RNA levels
in liver extracts (Fig. 6D) were analyzed, they were also found to be
increased in IL-15-treatedmice.However, as in lymphocytes andNK
cells, combination treatment with IFN- reduced IL-15-induced
PD-L1 expression. For intrahepatic dendritic cells, the sameobserva-
tion was made (data not shown).
PD-L1 blockade enhances the rescue effect of IL-15. Since the
PD-1–PD-L1 interaction has been implicated in the induction and
maintenance of peripheral tolerance (32, 33) and exhaustion (re-
viewed in reference 34), the effect of PD-L1 expression on the
effector functions of IHL expanded in IL-15-treated HBVTgmice
was investigated. An anti-PD-L1 blocking antibody was adminis-
tered intraperitoneally before and after injection of AAV–IL-15 or
a control (Fig. 7A). IHC performed on day 10 revealed large areas
of necrosis (Fig. 7B, top) and a simultaneous rise in ALT levels
(data not shown), as well as an almost-complete disappearance of
nuclear HBV core protein from the livers of animals treated with
IL-15 in combinationwith anti-PD-L1 (Fig. 7B, bottom). Analysis
of HBV DNA and RNA levels in the liver by quantitative PCR
showed that IL-15 alone or in combination with anti-PD-L1 sig-
nificantly reduced both HBV DNA (Fig. 7C) and RNA (Fig. 7D)
levels; the decrease in HBV RNA levels was significantly more
pronounced in the last group. Importantly, IL-15 plus PD-L1
blockade did not cause any tissue damage in wild-type mice. Un-
expectedly, PD-L1 blockade in mice that had received IFN-–
IL-15 treatment did not augment the infiltration of CD8 cells or
their response over that with combination treatment alone.Only a
very subtle effect, if any, on the reduction in the number of
HBcAg cells could be observed (data not shown).
Treatment with IL-15 plus IFN- can restore effector func-
tionandexpand theHBV-specificCD8population in someCHB
patients. To test if our findings would be transferable to chroni-
cally infected patients, a first in vitro study with PBMC samples
from a small cohort of patients with CHB was performed. Upon
stimulation in IL-2-supplemented medium in the presence or ab-
sence of an HBV peptide and the cytokines indicated in Fig. 8, the
addition of IL-15 resulted in unspecific bulk expansion of the live
CD8 T cell population in culture, while IFN- reduced the popu-
lation (Fig. 8A). Interestingly, as in the mouse study presented in
this paper, IL-15 partially compensated for this effect. In the pres-
ence of both cytokines, the overall proportion of HBV-specific
granzyme B-producing CD8 T cells (Fig. 8B), as well as the num-
ber of patients responding (Fig. 8C), was significantly increased
relative to that with either cytokine alone, especially in the pres-
ence of anHBVpeptide. The percentage of IFN--producingCD8
T cells uponHBV peptide stimulation was also increased by either
IFN- or IL-15 alone or by their combination in approximately
half of the 21 patients with CHB tested (Fig. 8D). Because of the
global CD8 expansion induced by the combination, the absolute
increase in HBV-specific CD8 T cells can be expected to be even
FIG 6 IL-15-induced expression of PD-1 and PD-L1 on liver infiltrates is reduced by IFN-. (A and B) Ten days after vector administration, PD-1 expression
on intrahepatic CD8 (A) and NK (B) cells was analyzed by flow cytometry. (C) Mean fluorescence intensity (MFI) of PD-L1 expressed on the surfaces of
purified hepatocytes. (D) Relative expression of PD-1 in RNA extracted from liver. Results are expressed as means (n 6)	 SEM. *, P
 0.05; **, P
 0.01; ***,
P
 0.001; ****, P
 0.0001.
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more significant. Further studies will require HLA/peptide dex-
tramers to dissect antigen-specific and bystander boosting in a
larger cohort of patients with CHB.
DISCUSSION
The hallmark of CHB is immune dysfunction, which results in
persistent infection (3, 4). Because of their stimulatory properties,
cytokines such as IFN- and IL-15 are considered good candidates
to aid the functional recovery of HBV-specific lymphocytes (17,
35), and recent work has also highlighted the potential of IFN- to
stimulate cell-intrinsic antiviral mechanisms in HBV-infected
hepatocytes (9). However, while IFN- therapy could strongly
drive the expansion and activation ofNK cells, it did not reactivate
HBV-specific T cells in CHB patients (7, 8). To investigate
whether it would be possible to increase the antiviral potential of
IFN- and to more efficiently activate the adaptive arm of the
immune response by combining it with the stimulatory cytokine
IL-15, anHBVTgmousemodel was used (20). Thesemice present
with dysfunctional, unresponsive HBV-specific CD8 T cells and
have beenwidely used to test immunostimulatory therapies aimed
at clearing HBV infection (22, 23, 36, 37).
The presence of cytoplasmic HBcAg is an indicator of active
HBV replication, whereas nuclear HBcAg is highly stable, persist-
ing in the absence of HBV replication (38, 39). In accordance with
previous findings (9), significant decreases in hepatic HBV DNA
and HBV RNA levels were obtained upon infection with AAV-
expressed IL-15 or IFN- alone, indicating an attenuation ofHBV
transcriptional activity and an abrogation of viral replication.
However, a high proportion of hepatocyte nuclei remained
HBcAg positive. In stark contrast, coinfection with both cytokines
resulted in the complete disappearance of HBV core protein from
hepatocytes, likely reflecting the successful initiation of an anti-
HBV immune response capable of controlling viral replication.
Hence, the efficacy of the combined therapy appeared to depend
on the synergistic activities of the two cytokines. In terms of cel-
lular immunity, in line with existing literature, IL-15 triggered a
robust expansion of the HBV-specific CD8 T cell population (17,
35), while IFN- induced differentiation into effector cytotoxic T
lymphocytes (CTL) without major cellular expansion (40). When
combined, HBV-specific CD8 T lymphocytes not only infiltrated
the liver in greater numbers but were also able to exert enhanced
cytotoxic activity, as reflected in increased serum ALT levels as
well as liver pathology. Importantly, no immune response against
an irrelevant H-2Kb peptide was detected, and no HBV- or OVA-
specific CD8T cell responses were present in the livers of C57BL/6
wild-type mice receiving the same treatment. In contrast, IHL
FIG 7 The combination of IL-15 therapy with PD-L1 blockade induces immune-mediated liver damage in HBVTg mice and a strong antiviral effect. (A)
Treatment scheme. (B) Representative images of liver sections stained with H&E (upper panels) or stained for core antigen (lower panels). (C and D) HBV (C)
and HBV RNA (D) relative levels on day 10 after vector administration. Results are normalized to GADPH levels. Data are presented as means (n 5)	 SEM.
*, P
 0.05; **, P
 0.01; ***, P
 0.001.
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fromHBVTgmice that had received IL-15 only, although numer-
ous, were not able to kill target cells in vivo or induce hepatocel-
lular necrosis. These data support the notion that liver damage
was at least partially mediated by the complementary effects of
IFN- and IL-15 on specific CD8 T cells and was not only a by-
stander effect. The successful recovery of HBV-specific CD8 ef-
fector cells with the combination treatment and their importance
for viral clearance were further corroborated upon their systemic
elimination by repeated anti-CD8 administration: the previously
observed antiviral effect of the cytokine coadministration disap-
peared, and HBc protein remained detectable in hepatocyte nu-
clei. Therefore, the viral clearance observed in the liver was not
due solely to the direct, antiviral effects of IFN- and/or IL-15.
Although in recent years, a potential antiviral role in chronic
HBV infection has been attributed to NK cells (27, 41), the ther-
apeutic approach presented here does not seem to support this
notion. Both alone and in combinationwith IL-15, IFN- resulted
in elevated NK cell numbers; however, in contrast to the results
obtained for CD8 cells, depletion of NK cells did not result in
significant recovery ofHBcAg hepatocytes. This finding is in line
with the observations of Yin et al. (19), who reported an NK-
independent effect of IL-15 on HBV.
FIG 8 Combination treatment with IL-15 and IFN- can restore partial CD8 effector function in some patients with chronic hepatitis B. PBMCs from patients
with CHB were cultured in IL-2-supplemented medium in the presence/absence of HBV peptide and the indicated cytokines. (A) Cumulative data showing the
percentage of CD8 T cells after 10 days of culture. Numbers of live CD8 T cells were measured by using a live/dead staining kit to exclude dead cells. (B)
Cumulative data showing the percentage of granzyme B-positive CD8 cells in the presence of IFN-, IL-15, or both in the absence or presence of HBV peptide
stimulation. (C andD) Individual responses of CHB patients, expressed as the percentage of CD8 cells producing granzyme B (C) or IFN- (D). Data represent
means	 SEM. *, P
 0.05; **, P
 0.01; ***, P
 0.001. Viral loads (VL), expressed as log10 IU per milliliter, and ALT levels, expressed as IU per liter, are given
below the graphs. n.a., not available; BLQ, below the limit of quantification.
Di Scala et al.
8572 jvi.asm.org October 2016 Volume 90 Number 19Journal of Virology
The exact role of PD-1–PD-L1 interaction in the induction and
maintenance of T cell tolerance, as well as in exhaustion, is still being
disputed and appears rather complex. However, it could be shown
thatPD-1blockadecanrestoreTcell functioneitherdirectly,byusing
blocking antibodies (42, 43), or indirectly, by blockade of IFN- (26,
31). In contrast to the latter reports, in ourhands, the high increase in
the level of PD-1 expressedon intrahepaticCD8- andNKcells from
HBVTg mice treated with AAV–IL-15 alone was significantly re-
duced inmice that had received the IL-15–IFN- combination ther-
apy. Thus, our data point to a role of IFN- in prohibiting IL-15-
induced PD-L1 upregulation, an effect that would be crucial for
licensing effector T lymphocytes to attack target cells. It was reported
previously that PD-1 does not directly mediate apoptosis but that its
expression levels correlate to the susceptibility of the cell to apoptosis
(29). In this study, pretreatment with common –chain cytokines,
IL-15 included, inducedPD-1upregulationbutdidnot interferewith
expansion, enhancement of some effector functions, or survival. This
treatment did, however, inhibit the exertion of certain effector func-
tions. The work presented here points to the synergy of IL-15 and
IFN- in overcoming these obstacles. How thismay happen in detail
requires more exploration. One possibility is the upregulation of
other stimulating cytokines/receptors on either theT cells themselves
or another cell type, such as dendritic cells. Our approach is corrob-
oratedbyarecentlypublishedstudy that investigated the rolesofBim,
PD-1, and Socs-1 in the onset and degree of acute liver damage in aT
cell receptor (TCR) transgenic model. The authors concluded that
strategies aimed at overcoming the block in effector function would
bemore efficient at clearing chronic hepatitis than those purely aim-
ing at prolonging survival (44).
The functional block could also be overcome by blocking the
PD-1–PD-L1 interaction and resulted in extensive areas of hepa-
tocellular necrosis and complete clearance of viral antigens from
the livers of IL-15-treated mice, indicating that this therapy is
equally effective in restoring the anti-HBV immune response.
Although the use of vector-delivered cytokines—and IL-15 in
particular—comes with many potential problems in a clinical set-
ting, our work demonstrated that the synergistic potential of the ap-
propriate combination of proliferation- and effector-inducing cyto-
kines can result in the recovery of dysfunctional T cell populations.
Thisworkprovidesnewinsight intohowto tuneexisting IFN- treat-
ment of CHB and also offers a therapeutic approach for chronic viral
infections and neoplastic conditions. As shown, preliminary results
from human studies indicate that this approach may be successful,
although the addition of IL-15 appears to promote global as well as
HBV-specificT cell expansion, as recently described forHIVpatients
(45). Such bystander T cell responsesmay increase the risk of hepatic
flares, in line with the necroinflammatory responses observed in our
mouse model, but could also contribute to a heterologous antiviral
response (46). Further indepth studieswill have tobedone toexplore
the synergistic effects of IFN- and other proliferation-promoting
common -chain cytokines and their potential efficacy for CHB pa-
tients.
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